First Eagle Investment Management Portfolio holdings
AUM
$50B
1-Year Return
21.83%
This Quarter Return
+5.36%
1 Year Return
+21.83%
3 Year Return
+77.85%
5 Year Return
+147.97%
10 Year Return
+284.97%
AUM
$39.3B
AUM Growth
-$63.5M
(-0.16%)
Cap. Flow
-$1.53B
Cap. Flow
% of AUM
-3.9%
Top 10 Holdings %
Top 10 Hldgs %
28.21%
Holding
374
New
38
Increased
90
Reduced
102
Closed
21
Top Buys
| 1 |
AB InBev
BUD
|
$207M |
| 2 |
TIF
Tiffany & Co.
TIF
|
$170M |
| 3 |
RDS.A
Royal Dutch Shell PLC ADS Class A
RDS.A
|
$117M |
| 4 |
Synchrony
SYF
|
$117M |
| 5 |
Elevance Health
ELV
|
$109M |
Top Sells
| 1 |
Intel
INTC
|
$505M |
| 2 |
Cintas
CTAS
|
$194M |
| 3 |
Northrop Grumman
NOC
|
$185M |
| 4 |
Abbott
ABT
|
$178M |
| 5 |
Becton Dickinson
BDX
|
$169M |
Sector Composition
| 1 | Financials | 15.61% |
| 2 | Materials | 14.32% |
| 3 | Industrials | 13.96% |
| 4 | Technology | 13.72% |
| 5 | Communication Services | 12.32% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
226
Ameriprise Financial
AMP
$46.1B
| $1.92M | ﹤0.01% |
21,324
| – | – |
|
227
Unum
UNM
$12.6B
| $1.91M | ﹤0.01% |
60,000
| – | – |
|
228
Xylem
XYL
$34.2B
| $1.75M | ﹤0.01% |
39,100
| – | – |
|
229
Industrial Select Sector SPDR Fund
XLI
$23.1B
| $1.68M | ﹤0.01% |
30,000
| – | – |
|
230
Monster Beverage
MNST
$61B
| $1.61M | ﹤0.01% |
60,000
-30,000
| -33% | -$804K |
|
231
MetLife
MET
$52.9B
| $1.59M | ﹤0.01% |
44,880
+26,030
| +138% | +$924K |
|
232
Apple
AAPL
$3.56T
| $1.54M | ﹤0.01% |
64,424
| – | – |
|
|
LORL
233
DELISTED
Loral Space and Communications, Inc.
LORL
| $1.46M | ﹤0.01% |
41,350
| – | – |
|
234
GE Aerospace
GE
$296B
| $1.4M | ﹤0.01% |
9,286
+6,928
| +294% | +$1.05M |
|
235
Summit Therapeutics
SMMT
$19.3B
| $1.38M | ﹤0.01% |
175,000
| – | – |
|
236
Limoneira
LMNR
$285M
| $1.35M | ﹤0.01% |
76,488
-900
| -1% | -$15.9K |
|
237
Unifirst Corp
UNF
$3.3B
| $1.34M | ﹤0.01% |
11,599
| – | – |
|
238
Philip Morris
PM
$251B
| $1.32M | ﹤0.01% |
13,000
| – | – |
|
239
Nuveen Global High Income Fund
JGH
$314M
| $1.3M | ﹤0.01% |
90,000
| – | – |
|
240
Gilead Sciences
GILD
$143B
| $1.29M | ﹤0.01% |
15,500
+6,300
| +68% | +$526K |
|
241
Corcept Therapeutics
CORT
$7.31B
| $1.22M | ﹤0.01% |
223,935
-171,735
| -43% | -$938K |
|
242
Iovance Biotherapeutics
IOVA
$901M
| $1.22M | ﹤0.01% |
+150,000
| New | +$1.22M |
|
243
RTX Corp
RTX
$211B
| $1.16M | ﹤0.01% |
17,937
-11,758
| -40% | -$759K |
|
244
AptarGroup
ATR
$9.13B
| $1.12M | ﹤0.01% |
14,129
| – | – |
|
|
TWX
245
DELISTED
Time Warner Inc
TWX
| $1.09M | ﹤0.01% |
14,846
| – | – |
|
246
Novartis
NVS
$251B
| $1.06M | ﹤0.01% |
14,338
| – | – |
|
|
247
Intel
INTC
$107B
| $1.01M | ﹤0.01% |
30,770
-15,410,660
| -100% | -$505M |
|
248
Liberty Media Series C
FWONK
$25.2B
| $1.01M | ﹤0.01% |
54,927
-304,212
| -85% | -$5.58M |
|
249
Donegal Group Class A
DGICA
$689M
| $984K | ﹤0.01% |
59,684
-4,384
| -7% | -$72.3K |
|
250
SPDR S&P Biotech ETF
XBI
$5.39B
| $982K | ﹤0.01% |
18,150
| – | – |
|